Urinary TGF-β1 and Serum AFP as Tumor Markers for Hepatocellular Carcinoma
Author Information
Author(s): J-F Tsai, JE Jeng, LY Chuang, ML Yang, MS Ho, WY Chang, MY Hsieh, ZY Lin, JH Tsai
Primary Institution: Kaohsiung Medical College; Institute of Biomedical Sciences, Academia Sinica
Hypothesis
The study evaluates the diagnostic application of urinary transforming growth factor-β1 (TGF-β1) and serum α-fetoprotein (AFP) levels in hepatocellular carcinoma (HCC).
Conclusion
TGF-β1 and AFP are independent tumor markers of HCC and can be used together to improve diagnostic accuracy.
Supporting Evidence
- TGF-β1 and AFP levels in HCC were higher than in cirrhosis alone.
- Both markers showed high specificity and improved diagnostic accuracy when used together.
- An inverse correlation was found between TGF-β1 and log AFP levels.
Takeaway
Doctors can use two tests, TGF-β1 and AFP, to better find liver cancer in patients who have liver disease.
Methodology
The study involved 94 patients with cirrhotic HCC and 94 matched patients with cirrhosis alone, measuring TGF-β1 and AFP levels.
Limitations
The study may overestimate the diagnostic accuracy as it focused on patients with histologically proven advanced HCC.
Participant Demographics
The study included 76 men and 18 women with ages ranging from 29 to 72 years.
Statistical Information
P-Value
0.0001
Confidence Interval
95% CI 1.04-1.12
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website